By targeting the miR-222-3p/TRPS1/ZEB1 axis and exosome-mediated signaling pathways, our study provides a foundation for developing innovative therapeutic strategies to mitigate RCC metastasis and improve patient outcomes. This evidence concerns the gene TRPS1 and renal cell carcinoma.